Out-license Agreements - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended				3 Months Ended	12 Months Ended
	Oct. 31, 2021	Sep. 30, 2022	Jan. 31, 2022	Oct. 31, 2021	Mar. 31, 2021	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 02, 2022
License, Collaboration and Manufacturing Agreements [Line Items]
License and collaboration revenue							$ 63,573	$ 20,340	$ 0
Deferred revenue							0
Development or sales-based milestone payments earned or received							0
Bayer License Agreement
License, Collaboration and Manufacturing Agreements [Line Items]
Upfront cash payment received									45,000
Additional upfront reimbursement payment for research and process development									15,000
Determined upfront payment for license in order to evaluate transaction price									45,000
Determined research and process development activities in order to evaluate transaction price									15,000
Determined additional specified translational activities in order to evaluate transaction price									$ 5,000
Determined fee constituted entire consideration included in transaction price							13,100
Bayer Technology Transfer Agreement
License, Collaboration and Manufacturing Agreements [Line Items]
License Agreement Amount Invoiced Percentage			40.00%			20.00%
License Agreement Invoiced Amount			$ 6,100			$ 3,100
License agreement total fee					$ 15,300	$ 15,300
Bayer Manufacturing Agreement
License, Collaboration and Manufacturing Agreements [Line Items]
Estimated Supply Price Amount Invoiced					$ 6,600
License Agreement Percentage O F Estimated Supply Price To Be Invoiced Upon Delivery					50.00%
Invoiced Upon Written Acceptance Of Binding Purchase Order Percentage					50.00%
Manufacturing services					$ 13,100
Liabilities Subject To Compromise Early Contract Termination Fees										$ 4,200
License and collaboration revenue							61,800	19,800
Deferred revenue								$ 51,500
Bayer Agreements
License, Collaboration and Manufacturing Agreements [Line Items]
License and collaboration revenue							61,800
Pierre Fabre Commercialization Agreement
License, Collaboration and Manufacturing Agreements [Line Items]
Upfront cash payment received				$ 45,000
Royalty eligible to receive term after first commercial sale	12 years
License and collaboration revenue							1,800
Deferred revenue							85,000
Development or sales-based milestone payments earned or received							$ 40,000
Years of manufacturing and supplying cost							7 years
Determined upfront payment constituted entire consideration included in transaction price							$ 45,000
Payment exchange reduction Amount		$ 30,000
Milestone payments							40,000
Pierre Fabre Commercialization Agreement | Current Liabilities
License, Collaboration and Manufacturing Agreements [Line Items]
Deferred revenue							8,000
Pierre Fabre Commercialization Agreement | Long-Term Liabilities
License, Collaboration and Manufacturing Agreements [Line Items]
Deferred revenue							$ 77,000
Pierre Fabre Commercialization Agreement | Maximum
License, Collaboration and Manufacturing Agreements [Line Items]
Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones	$ 308,000			$ 308,000